Revatio

Revatio is a brand name of sildenafil, approved by the FDA in the following formulation(s):

REVATIO (sildenafil citrate - solution; intravenous)

• 
  Manufacturer: PFIZER
  
  Approval date: November 18, 2009
  
  Strength(s): EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML) ^[RLD]

REVATIO (sildenafil citrate - tablet; oral)

• 
  Manufacturer: PFIZER
  
  Approval date: June 3, 2005
  
  Strength(s): EQ 20MG BASE ^[RLD]

Has a generic version of Revatio been approved?

No. There is currently no therapeutically equivalent version of Revatio available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Revatio. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pyrazolopyrimidinone antianginal agents
  Patent 5,250,534
  Issued: October 5, 1993
  Inventor(s): Bell; Andrew S. & Brown; David & Terrett; Nicholas K.
  Assignee(s): Pfizer Inc.
  Compounds of the formula: ##STR1## wherein R.sup.1 is H, C.sub.1 -C.sub.3 alkyl, C.sub.3 -C.sub.5 cycloalkyl or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.2 is H, C.sub.1 -C.sub.6 alkyl optionally substituted by OH, C.sub.1 -C.sub.3 alkoxy or C.sub.3 -C.sub.6 cycloalkyl, or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.3 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 alkenyl, C.sub.3 -C.sub.6 alkynyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.6 perfluoroalkyl or (C.sub.3 -C.sub.6 cycloalkyl)C.sub.1 -C.sub.6 alkyl; R.sup.4 taken together with the nitrogen atom to which it is attached completes a pyrrolidinyl, piperidino, morpholino, or 4-N-(R.sup.6)-piperazinyl group; R.sup.5 is H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.3 alkoxy, NR.sup.7 R.sup.8, or CONR.sup.7 R.sup.8 ; R.sup.6 is H, C.sub.1 -C.sub.6 alkyl, (C.sub.1 -C.sub.3 alkoxy) C.sub.2 - C.sub.6 alkyl, hydroxy C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 N)C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 NCO)C.sub.1 -C.sub.6 alkyl, CONR.sup.7 R.sup.8, CSNR.sup.7 R.sup.8 or C(NH)NR.sup.7 R.sup.8 ; R.sup.7 and R.sup.8 are each independently H, C.sub.1 -C.sub.4 alkyl, (C.sub.1 -C.sub.3 alkoxy)C.sub.2 -C.sub.4 alkyl or hydroxy C.sub.2 -C.sub.4 alkyl; and pharmaceutically acceptable salts thereof, are selective cGMP PDE inhibitors useful in the treatment of cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.
  
  Patent expiration dates:
  
  
  • March 27, 2012
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 27, 2012
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 7, 2012 - TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING
  
  
  • November 7, 2012 - PEDIATRIC EXCLUSIVITY
  
  
  • November 20, 2012 - NEW DOSAGE FORM
  
  
  • May 20, 2013 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Revatio Consumer Information (Drugs.com)
• Revatio Consumer Information (Wolters Kluwer)
• Revatio Injection Consumer Information (Wolters Kluwer)
• Revatio Consumer Information (Cerner Multum)
• Revatio Advanced Consumer Information (Micromedex)
• Revatio Intravenous Advanced Consumer Information (Micromedex)
• Sildenafil Consumer Information (Wolters Kluwer)
• Sildenafil Injection Consumer Information (Wolters Kluwer)
• Sildenafil Consumer Information (Cerner Multum)
• Sildenafil Advanced Consumer Information (Micromedex)
• Sildenafil Intravenous Advanced Consumer Information (Micromedex)
• Sildenafil Citrate AHFS DI Monographs (ASHP)